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Allosteric Optical Control of a Class B G-Protein-Coupled Receptor
Johannes Broichhagen, Natalie R. Johnston, Yorrick von Ohlen, Helena Meyer-Berg,
Ben J. Jones, Stephen R. Bloom, Guy A. Rutter, Dirk Trauner,* and David J. Hodson*
Abstract: Allosteric regulation promises to open up new
therapeutic avenues by increasing drug specificity at G-protein-
coupled receptors (GPCRs). However, drug discovery efforts
are at present hampered by an inability to precisely control the
allosteric site. Herein, we describe the design, synthesis, and
testing of PhotoETP, a light-activated positive allosteric
modulator of the glucagon-like peptide-1 receptor (GLP-1R),
a class B GPCR involved in the maintenance of glucose
homeostasis in humans. PhotoETP potentiates Ca2+, cAMP,
and insulin responses to glucagon-like peptide-1 and its
metabolites following illumination of cells with blue light.
PhotoETP thus provides a blueprint for the production of
small-molecule class B GPCR allosteric photoswitches, and
may represent a useful tool for understanding positive
cooperativity at the GLP-1R.
The incretin hormone glucagon-like peptide-1 (GLP-1) is
released from enteroendocrine L-cells in the intestine,[1] from
where it binds cognate receptors to promote the survival of
pancreatic beta cells, insulin release, and weight loss.[2] For
these reasons, incretin mimetics based on GLP-1 have
become widely-prescribed drugs for the restoration of
normal glucose levels in type 2 diabetes (T2D),[3] a socio-
economically costly syndrome affecting almost 400 million
individuals worldwide.[4]
The glucagon-like peptide 1 receptor (GLP-1R) is
a class B G-protein-coupled receptor (GPCR) that is primar-
ily coupled to adenylate cyclase activity and 3’-5’-cyclic
adenosine monophosphate (cAMP) accumulation,[5] as well
as intracellular Ca2+ fluxes.[6] Recently, an allosteric site has
been described for this receptor that allows fine modulation
of orthosteric ligand binding.[7] The ligand-dependent allo-
steric activator 4-(3-(benzyloxy)phenyl)-2-(ethylsulfinyl)-6-
(trifluoromethyl)pyrimidine (BETP) potentiates Ca2+ mobi-
lization in response to GLP-1(7-36)NH2,
[7,8] the active ami-
dated form of GLP-1. By contrast, BETP amplifies cAMP
generation in response to GLP-1(9-36)NH2,
[7, 8] a metabolite
and weak partial GLP-1R agonist. Such interactions are
therapeutically desirable, since drugs that target the GLP-1R
allosteric site may improve receptor specificity, thereby
reducing side effects.[7–9] However, their investigation is at
present hindered by a lack of specific research tools for the
fine control of allosterism and receptor movement. Photo-
pharmacology is well-suited to this task, since it relies on the
properties of light to precisely deliver drug activity in space
and time.[10]
Herein, we describe the development and testing of
PhotoETP, a light-activated positive allosteric modulator that
allows optical control of GLP-1R signaling and insulin
secretion by using blue light (Figure 1A).
We set out to confer photoswitching on the GLP-1R
allosteric site by subjecting BETP to our “azologization”
strategy[11] (Figure 1B; see also Figure S1 in the Supporting
Information). By coupling commercially available chloropyr-
imidine 1 and boronic acid 2 under Suzuki–Miyaura con-
ditions, bisaryl thioether 3 was obtained in a yield of 95%.
After oxidizing the sulfur atom with mCPBA to its sulfone
counterpart 4 in a yield of 90%, it was exchanged in an
aromatic substitution with ethyl sulfide to give ethyl thioether
5 in a yield of 55%. Subsequent oxidation with one equivalent
of mCPBA gave access to sulfoxide 6 (96%), which was
deprotected with TFA before undergoing Mills reaction with
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nitrosobenzene to produce PhotoETP in a yield of 54% over
two steps. Attempts to crystallize PhotoETP from MeOH
yielded compound 7, thus providing further evidence for the
electrophilicity of PhotoETP (Figure 1C). Crystals suitable
for X-ray crystallography were obtained for both 3 and 7
(Figure 1D).
The UV/Vis spectrum of PhotoETP under illumination at
l= 440 nm (trans, blue) and l= 330 nm (cis, gray) demon-
strated the presence of wavelength-dependent switching
(Figure 2A), as expected for a meta-azobenzene system
(Figure 2B). Photoswitching could be repeated over several
cycles with reasonably fast kinetics (tcis= 204.2: 7.3 s; ttrans=
54.5: 2.9 s) and without obvious fatigue (Figure 2C), and the
cis and trans isomers were separated by LC–MS analysis
(Figure 2D). Together, these features of PhotoETP provide
a basis for the allosteric photocontrol of GLP-1R activity.
We next examined whether PhotoETP was able to yield
optical control over GLP-1(9-36)NH2-induced cAMP gener-
ation. Similarly to BETP, trans-PhotoETP potentiated cAMP
rises in response to GLP-1(9-36)NH2 [EC50(trans-Photo-
ETP)= 163.3 nm; EC50(BETP)= 99.5 nm]. Importantly, this
activity could be switched off using UV illumination to induce
cis-isomer formation (Figure 3A; unable to calculate EC50).
The extent of photoswitching is similar to that recently
reported for an allosteric modulator of the metabotropic
glutamate receptor mGluR5, a class C GPCR.[12] The effect of
PhotoETP on cell viability was determined in islets by using
necrosis and apoptosis assays in the dark. At the concen-
tration used throughout the present study, PhotoETP did not
induce significant necrosis (Figure 3B) or apoptosis (Fig-
ure 3C), as measured using propidium iodide incorporation
and terminal deoxynucleotidyl transferase dUTP nick end
labelling (TUNEL), respectively. By contrast, treatment with
staurosporine or thapsigargin positive controls resulted in
large increases in necrotic and apoptotic indices (Fig-
ure 3B,C). Furthermore, levels of cleaved caspase-3, an
enzyme involved in the proteolytic cleavage of critical
intracellular effectors including poly (ADP-ribose) poly-
merase, were unaffected by incubation with PhotoETP
(Figure S2).
Next, photoswitching of intracellular Ca2+ dynamics was
assessed by using PhotoETP directly in beta cells residing
within intact islets of Langerhans. Whereas cis-PhotoETP
(l= 350 nm) showed little effect, the trans isomer (l=
440 nm) potentiated GLP-1(7-36)NH2-induced increases in
Ca2+ levels (Figure 3D–G), as previously described for cAMP.
The latter could be abolished by using either low glucose
(Figure S3A,B) or the specific GLP-1R antagonist exendin 9–
39 (Figure S3C,D). In all cases, results in islets were replicated
in MIN6 beta cells subjected to high-throughput Ca2+ screens
(Figure 3H–J). When using batch-incubated islets, trans-
PhotoETP potently amplifiedGLP-1(9-36)NH2-induced insu-
Figure 1. Design and synthesis of PhotoETP. a) An azobenzene unit is
installed on the positive allosteric modulator BETP to produce Photo-
ETP. This allows Ca2+ and cAMP responses to GLP-1 and its inactive
metabolites to be potentiated following illumination with UV or blue
light. b) Six-step synthetic pathway for the production of PhotoETP.
c) Crystallization of PhotoETP as its methoxy counterpart (7) from
MeOH. d) Crystal structures for PhotoETP congener 7 (CCDC 1420305
contain the supplementary crystallographic data for this paper. These
data can be obtained free of charge from The Cambridge
Crystallographic Data Centre) and its precursor bisaryl thioether 3
(CCDC 1420306 contain the supplementary crystallographic data for
this paper. These data can be obtained free of charge from The
Cambridge Crystallographic Data Centre).
Figure 2. Characterization of PhotoETP. a) Isomerization of PhotoETP
between its trans- and cis- states with blue light or UV irradiation,
respectively. b) UV/Vis spectra of PhotoETP in DMSO following
illumination at l=440 nm (blue), l=330 nm (grey), or under dark
conditions (black). c) Robust photoswitching between trans- and cis-
PhotoETP induced with l=440 nm and l=330 nm, respectively.
d) LC–MS trace of PhotoETP in the dark (black) and after exposure to
UV light (l=350 nm; gray).
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lin secretion (Figure 4A), whereas cis-PhotoETP was less
effective as an allosteric modulator (Figure 4A). By contrast,
BETP, cis-PhotoETP, and trans-PhotoETP all augmented
insulin secretion in response to GLP-1(7-36)NH2 by almost 2-
fold (Figure 4B), with no evidence of photocontrol.
PhotoETP was almost 20% cis-enriched under benchtop
conditions (1H NMR spectrum; see the Supporting Informa-
tion), whereas the UV/Vis spectra revealed a more pro-
nounced p–p* band in the dark (see Figure 2B). This finding
can be explained by consulting a model of the glucagon
receptor mutant F345C bound to BETP, where a twisted
conformation of the benzylether is found to be the lowest
energy state.[7] Such a conformation may also be adopted by
cis-PhotoETPowing to its higher affinity for covalent binding.
However, in contrast to BETP, which can reorganize its
molecular shape in response to orthosteric ligand binding,
PhotoETP would remain trapped in its cis state until
illumination to induce trans-isomerization. Although the
exact isomer ratio at the receptor is difficult to determine
empirically, such properties may nonetheless afford fine
control over photoswitching, with dark conditions, 440 nm
illumination, and 350 nm illumination leading to graded Ca2+
responses (Figure S4). Further studies using rigid E- and Z-
stilbene bioisosteres of PhotoETP will be required to better
delineate the mechanisms involved.
The data presented herein outline a straightforward
synthetic strategy for the production of a blue-light-activated
positive allosteric modulator, which enables photocontrol of
GLP-1R activity through a feedforward loop encompassing
the orthosteric site (Figure 1A). Although similar “allos-
witches” have been described for ionotropic and metabo-
tropic mGluRs,[12,13] this is the first demonstration of their use
in a therapeutically relevant class B GPCR. Using a combi-
nation of Ca2+, cAMP, and insulin assays in CHO-GLP-1R
and MIN6 cells, as well as islets of Langerhans, we were able
to show that PhotoETP allows photoswitching of responses to
GLP-1(7-36)NH2 and its less active breakdown product,
GLP-1(9-36)NH2, with similar potency to native BETP.
Notably, PhotoETP displays unusual behavior in cells,
where it shows an enriched cis content when interacting
with its target in the dark. Indeed, the more active trans
isomer has to be photochemically induced by irradiation with
blue light. As a result of these properties, PhotoETP, together
with the recently described signal-biased GLP-1R photo-
switch LirAzo,[14] may enable the precise dissection of
allosteric–orthosteric cooperativity, molecular movement,
and binding.
Both BETP and PhotoETP were more effective at
potentiating GLP-1(9-36)NH2-induced compared to GLP-
1(7-36)NH2-induced insulin secretion. This suggests that
cAMP rather than Ca2+ is the primary driver of the “incretin
effect”, and is consistent with previous results obtained using
LirAzo.[14] Intriguingly, optical control of insulin release could
only be observed in GLP-1(9-36)NH2- and PhotoETP-treated
islets, where blue light provoked a two-fold higher response
than UV illumination. Although the exact reasons for this
remain unknown, it may reflect an inability to detect
relatively small isomer-induced differences in intracellular
Ca2+ versus cAMP concentration at the level of secretion in
islets.
BETP was susceptible to UV-A-induced but not white-
light-induced reactions, thus making it a poor control for
photoswitching purposes (see Figure S5–S8). In contrast,
PhotoETP was remarkably robust. This protective effect
Figure 3. Optical control of cAMP and Ca2+ signals. a) Illumination at
l=440 nm, but not l=350 nm (UV), optically modulates GLP-1(9-
36)NH2-induced cAMP generation in CHO-GLP-1R cells (n=4
repeats). b) Incubation of MIN6 beta cells with PhotoETP for 3 h does
not alter cell viability (n=8 repeats, +ve=positive control: stauro-
sporine or thapsigargin). c) As for (b) but with apoptosis measured
(n=3 repeats). d–g) Illumination at l=440 nm, but not l=350 nm,
modulates GLP-1(7-36)NH2-induced Ca
2+ increases in intact Photo-
ETP-treated islets (n=9 recordings from 3 animals). h–j) As for (d)–
(g), but in MIN6 beta cells (n=8 repeats; RFU= relative fluorescence
units, AUC=area under the curve; ATP 10 mM; positive control). In all
cases, GLP-1(7-36)NH2 was co-applied at 10 nm in the presence of 8–
11 mm (islets) or 17 mm (MIN6) d-glucose. PhotoETP and BETP were
applied at 50 mm. NS: non-significant or **P<0.01 versus cis-Photo-
ETP or DMSO; one-way ANOVA. Values represent the mean:SEM.
Scale bar, 75 mm.
Figure 4. Optical control of insulin secretion. a) trans-PhotoETP is
more effective than cis-PhotoETP at potentiating GLP-1(9-36)NH2-
induced insulin secretion. b) trans-PhotoETP and cis-PhotoETP similarly
potentiate GLP-1(7-36)NH2-induced insulin secretion. In all cases,
PhotoETP and BETP were applied at 50 mm with either GLP-1(9-
36)NH2 100 nM or GLP-1(7-36)NH2 10 nM, as indicated. d-glucose
was present at 11 mM. NS: non-significant or *P<0.05 versus cis-
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stems from the azobenzene unit, which preferentially harvests
UV-A photons with its p–p* band to undergo isomerization.
In other words, by installing an azobenzene moiety onto
BETP, side reactions can be quenched and the resulting
molecule stabilized. Nevertheless, the UV-A-induced rear-
rangement of BETP to its sulfenic ester counterpart via
a Meisenheimer complex, and the accompanying transforma-
tion, is in itself an interesting finding (Figure S5,S6). Although
related rearrangements of sulfoxides have been reported,[15]
sulfenic esters have not been isolated as products owing to the
low (UV-C) wavelengths used in these experiments. Such
rearrangements are relevant for drug activity, as best exem-
plified by acid-activation of the irreversible proton-pump
inhibitor omeprazole (Prilosec).[16]
In summary, we showcase PhotoETP, a light-activated
modulator for allosteric optical control of GLP-1R function,
and highlight the requirement to run parallel control experi-
ments with benchmark drugs in photopharmacology. Photo-
ETP, or optimized derivatives thereof, may be useful in drug-
discovery programs aimed at unraveling the complexity of
allosterism and class B GPCR signaling.
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